🔗 Share this article

Given that America proceeds with unprecedented changes to its vaccination schedules, a particular individual appears in a surprising turn: Tracy Beth Høeg, an American of Danish descent sports medicine doctor and public health researcher who rose to prominence by expressing skepticism about COVID-19 vaccines in the global health crisis and has concentrated on possible fatalities following Covid immunization in her brief tenure at the US Food and Drug Administration (FDA).

Planned Changes to Childhood Immunization Schedule

Health officials had intended to unveil major revisions to the pediatric immunization program earlier this month, bringing the US with the Danish vaccine program, according to reports – a significant shift that would put the US out of alignment with a large portion of the world with little proof for improved outcomes. The planned update has been delayed until the new year.

In place of Vinay Prasad, Dr. Høeg is set to present at the meeting. She was recently named acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to head the office this year.

A New Direction at the Regulatory Body

This interim role may indicate a closer partnership between the drug and vaccine divisions as Dr. Høeg and Dr. Prasad solidify control at the FDA – and it signals a greater focus upon rolling back already-approved vaccines at the FDA.

Dr. Høeg has repeatedly called for discontinuing specific pediatric vaccine recommendations in the US so as to align more in line with the Danish model, a country with comprehensive healthcare and a citizenry about the size of Wisconsin’s.

To date public appearances, she has kept her attention on immunizations – traditionally the domain of Dr. Prasad, head of the FDA’s CBER – as opposed to drug regulation.

Concerns Over Expertise

The appointee has no obvious experience in drug development, oversight or management, which has been customary for past leaders of the CBER. She has served at the FDA as a senior adviser to the FDA chief and CBER since earlier this year.

“She appears not to have any of the qualifications” for running the drug-regulation department, said Jonathan Howard. “She lacks experience running a scientific study. She has no expertise in running a major agency. She has no expertise in industry regulation.”

Previous commissioners of CBER would “grasp regulatory frameworks and the science of drug development”, commented a former acting FDA commissioner. “Clearly, she doesn’t have the sort of resume that prior appointees who ran the center have had.”

The drug center has an enormous workload at the FDA, she pointed out.

“Everybody just focuses on the innovative therapies, but the generic drug division authorizes thousands of off-brand pharmaceuticals. There is also a biosimilars division, non-prescription drug unit and other areas, and each of these need to be managed,” she said. “The thing you overlook, that is the part that I always told people is going to come back to haunt you.”

Additionally, a substantial leadership component to the position, which supervises more than 5,000 employees. “It’s a huge leadership role, if you execute it properly,” the former official added.

Agency Reaction and Controversial Initiatives

Regarding questions about Dr. Høeg's qualifications and whether this selection indicates increased cooperation among agency officials on immunizations, a spokesperson said that the “concerns rely on inaccurate assumptions”.

“This background aligns with the duties of her job,” the spokesperson stated, citing the period Dr. Høeg spent advising the FDA commissioner on “medication safety and oversight research, including predictive safety algorithms and immunization monitoring”.

As acting director, Dr. Høeg takes over the commissioner’s recently launched fast-track approval initiative, a controversial rapid therapy clearance system that reportedly concerned her predecessors. “How are these therapies being picked for this expedited pathway? Who is making the calls?” Dr. Howard questioned. “There’s a lot of secrecy going on at the regulatory body right now.”

In general, he said, “the Food and Drug Administration looks to be trending towards more relaxed regulations of all drugs, aside from vaccines.”

Established Past Work on Immunizations

With vaccines, Høeg has a more established, if problematic, past, Howard observe. She authored a analysis using unconfirmed volunteer-provided data to determine the rate of myocarditis following Covid vaccination. She consulted for the state of Florida surgeon general Joseph Ladapo, who was said to have changed statistics to suggest Covid vaccines are pose a greater threat than they are.

Among her “desired changes” for the current administration encompassed changing guidelines for recently developed shots and halting “unnecessary” vaccines, she stated after the election on a online show. At the FDA, Høeg has reportedly suggested barring teenage boys from getting Covid vaccinations.

“She is an thorough true believer who starts off with her conclusions and reverse-engineers to accommodate the evidence in a extremely misleading, dishonest manner,” Dr. Howard stated.

Taking Control and a “Push for Payback”

Høeg aligned with other dissenters, {like|